Treatment with Briumvi Improves Fatigue in Patients with Relapsing Multiple Sclerosis

Post hoc analyses of the phase 3 ULTIMATE I and II (NCT03277261 and NCT03277248) trials showed a significant reduction from baseline Fatigue Impact Scale (FIS) total score at all time points for participants with relapsing multiple sclerosis (RMS) treated with Briumvi (ublituximab; TG Therapeutics, New York, NY) compared with those treated with Aubagio (teriflunomide; Sanofi, Bridgewater, NJ) (week 24: –6.4 vs -3.1, P=.027; week 48: 8.2 vs –4.4, P=.018; week 96: –9.1 vs –4.4, P=.008). These results were presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

In both the phase 3 ULTIMATE I (n=549) and II (n=545) trials, RMS participants received either 450 mg intravenous 1 hour infusions of Briumvi every 24 weeks (following day 1 infusion of 150 mg and day 15 infusion of 450 mg) or 14 mg Aubagio orally once daily for 96 weeks. Subgroup analysis revealed significant improvement in fatigue symptoms in favor of Briumvi at week 48 and week 96 for RMS participants with baseline FIS scores less than or equal to median, whereas no significant difference was observed for the subgroup with baseline FIS score greater than median at any time point. The results of these trials demonstrate that Briumvi significantly improves fatigue compared with Aubagio at all time points, with a stronger treatment impact for RMS participants with lower baseline FIS scores. Researchers from this study were from the University of Colorado, the University of South Florida, TG Therapeutics, and Hope Neurology MS Center.